Perventricular device closure of muscular ventricular septal defects on the beating heart: technique and results  by Bacha, Emile A et al.
Perventricular device closure of muscular ventricular
septal defects on the beating heart: Technique and results
Emile A. Bacha, MDa
Qi-Ling Cao, MDb
Joanne P. Starr, MDa
David Waight, MDb
Makram R. Ebeid, MDc
Ziyad M. Hijazi, MDb
Objective: Both surgical management and percutaneous device closure of muscular
ventricular septal defects have drawbacks and limitations. This report describes our
initial experience with intraoperative device closure of muscular ventricular septal
defects without cardiopulmonary bypass in 6 consecutive patients.
Methods: A median sternotomy or a subxiphoid minimally invasive incision was
performed. Under continuous transesophageal echocardiographic guidance, the right
ventricle free wall was punctured, and a wire was introduced across the largest
defect. The Amplatzer (AGA Medical Corporation, Golden Valley, Minn) muscular
ventricular septal defect occluding device (a self-expandable double-disk device)
was used. An introducer sheath was fed over the wire, with the sheath tip positioned
in the left ventricle cavity. The device was then advanced inside the sheath and
deployed by retracting the sheath. Associated cardiac lesions, if any, can then be
repaired during cardiopulmonary bypass. A similar technique can also be applied for
periatrial closure of complex atrial septal defects.
Results: The initial 6 patients are presented. Cardiopulmonary bypass was not
needed in any patient for placement of the device and needed in 4 patients for repair
of concomitant malformations only (double-outlet right ventricle, aortic arch hyp-
oplasia, pulmonary artery band removal). No complications from using this tech-
nique occurred. Discharge echocardiograms showed no significant shunting across
the ventricular septum.
Conclusions: Perventricular closure of multiple muscular ventricular septal defects
is safe and effective. We believe that this could become the treatment of choice for
any infant with muscular ventricular septal defects or any child with muscular
ventricular septal defect and associated cardiac defects.
Despite recent improvements,1,2 surgical therapy of muscular ven-tricular septal defects (MVSDs), especially when multiple orrequiring left ventriculotomy for closure, is still associated withsignificant long-term morbidity and mortality.1-3 When presentwith other complex heart lesions such as double-outlet rightventricle (DORV), for example, multiple MVSDs have been
found to be an independent risk factor for early mortality.4,5 In the long-term, heart
transplantation is sometimes required because of persistent ventricular dysfunc-
tion.1,2,6 Recent results of percutaneous device closure of MVSDs have been very
encouraging.7 However, the percutaneous approach can be challenging because of
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low patient weight (infants 5 kg) or poor vascular access.
In addition, in small infants, the passage of large delivery
catheters may result in rhythm disturbances and hemody-
namic compromise. Efforts have been made to combine
catheterization and surgical techniques. Four series of in-
traoperative closure using double-umbrella devices have
been reported.6,8-10 Overall results were not satisfactory,
with mortality and failure rates of 14% to 25% and 20% to
40%, respectively. The common approach to all was that the
devices were placed under direct vision, after cardiopulmo-
nary bypass (CPB) and cardioplegic arrest. Some deaths
resulted from residual shunting and from low cardiac output
despite complete closure.
This report describes our consecutive experience with a
technique that does not require CPB to deal with this diffi-
cult clinical problem. The device used was the Amplatzer
congenital MVSD device (AGA Medical Corporation,
Golden Valley, Minn), a self-expandable double-disk de-
vice made from nitinol wire mesh. The device size corre-
sponds to the waist (7 mm long) diameter of the device.
Both left ventricle (LV) and RV disks are 4 mm larger than
the waist.
Material and Methods
The heart was approached through a median sternotomy or, as in
the latest patient, a subxiphoid minimally invasive incision without
sternotomy. Under continuous transesophageal echocardiography
(TEE) guidance, the best location for RV puncture was chosen,
being careful to stay away from any papillary muscles but far
enough from the septum so as to approach it from a perpendicular
angle with the needle and wire (Figures 1 and 2). A 5-0 polypro-
pylene purse-string was placed at the chosen location. An 18-G
needle (Cook Inc, Bloomington, Ind) was introduced into the RV
Figure 1. Perventricular VSD device closure in an infant with DORV, pulmonary stenosis, subaortic VSD, and
multiple muscular apical VSDs. (A) Multiple apical defects (smaller arrows) and subaortic VSD (large arrow). (B)
The wire is positioned across the largest apical defect. (C) The sheath is positioned with its tip in the LV cavity.
The device is then pushed in and deployed by slowly pulling the sheath back. (D) Postoperative TEE. The device
has been deployed, and the subaortic VSD patch can also be seen in place.
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cavity and directed toward the defect to be closed. A 0.035-inch
angled glide wire (Boston Scientific; Medi-Tech, Natick, Mass)
was passed through the needle and manipulated into the LV cavity
through the defect. The needle was then removed keeping the wire
in location. A 7F to 10F short (8-13 cm) introducer sheath with a
dilator was fed over the wire and carefully advanced into the LV
cavity. Care must be taken not to go too deep into the heart because
the introducer and dilator are stiff instruments made for percuta-
neous puncture and thus are quite long and could easily perforate
the LV wall despite being guided by the wire (straightening of the
wire by the dilator). The dilator was removed, and the sheath tip
was positioned in the LV cavity (Figure 1C). The appropriate
device size was chosen to be 1 to 2 mm larger than the VSD size
as assessed by TEE. The device was presoaked in nonheparinized
blood for 10 minutes to allow for the tiny fenestrations of the
nitinol mesh to thrombose. The device was then screwed to the
cable and pulled inside a 6-9 Fr loader under blood seal to prevent
any air bubbles. The device was advanced inside the short delivery
sheath until it was seen by TEE to be close to the tip of the delivery
sheath. The LV disk was deployed in mid-LV cavity by gentle
retraction of the sheath over the cable. The entire assembly (cable/
sheath) was withdrawn gently until the LV disk was against the
septum. Further retraction of the sheath over the cable would
deploy the waist inside the septum. Continuous TEE to confirm the
device position is of paramount importance. Once the position was
confirmed, further retraction of the sheath to expand the RV disk
was performed. If device position was satisfactory, the device was
released by counterclockwise rotation of the cable using the pin
vise. A complete TEE study in multiple planes was performed to
confirm device placement, assess for residual shunting, and discern
any obstruction or regurgitation induced by the device.
Clinical Summaries
Informed consent was obtained from the patients’ guardians.
The study was approved by the hospital investigation review
board and was part of a Food and Drug Administration Inves-
tigation Device Exemption clinical trial. The study started in
September 2002. Selection criteria were (1) the presence of
cardiac lesions necessitating operative repair (in addition to an
MVSD) and (2) patients with contraindications to percutaneous
device closure of MVSDs (eg, infants or patients with poor
vascular access).
No patient was converted from a perventricular approach to an
open approach. Standard pediatric cardiac surgical intraoperative
and postoperative monitoring were used (Table 1).
Discussion
One successful case of intraoperative perventricular device
closure on the beating heart has been reported in a baby.12
This is the first reported series of consecutive intraoperative
VSD device closure without CPB. In previous reports of
intraoperative device closures, the difficulties in delivering
the device or having to suture the device were specifically
quoted as a factor in poor outcomes.6,8,9 The present tech-
nique’s safety has been validated in animal experiments.13
Although not formally measured, the time needed to cross
the VSD and position the device was less than 20 minutes in
all cases. This compares very favorably with the longer
procedure times when the equivalent maneuver is attempted
in the catheterization laboratory. An advantage of this tech-
Figure 2. Perventricular VSD device closure in a banded child with multiple right-sided apical openings converg-
ing into a single large left-sided opening. (A) Short-axis view of the apical septum. The inferior edge of the
moderator band (2) could be easily mistaken for the superior edge of the VSD (dotted arrow). In fact, the true
superior/anterior border of the VSD extends further (dashed arrow). It becomes clear that multiple openings on the
right converge into a single very large VSD on the left. (1) Posterior papillary muscle, (2) moderator band, (3)
anterior papillary muscle. (B) The LV disk is deployed, occluding the single left-sided opening. The RV disk was
deployed within the apical RV trabeculations.
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nique compared with standard surgical techniques is the
avoidance of CPB in patients who often have ventricular
dysfunction. If associated cardiac lesions are present, a
marked reduction in CPB and cardioplegic arrest time is
achieved. As illustrated in patient 6, perventricular device
closure of a previously underestimated MVSD resulted in
avoidance of repeated cardiologic arrest in a patient who
already had a long crossclamp time. Other advantages in-
clude avoidance of transection of the moderator band or
other RV muscle bundles, immediate confirmation of ade-
quate closure, and avoidance of any ventricular incisions. In
the absence of associated defects, a minimally invasive
approach, such as a subxiphoid incision (1-2 cm), can be
easily used (patient 5). Compared with percutaneous ap-
proaches, it has no weight and no vascular access limita-
tions. Particularly in malformations with unusual septal
TABLE 1. Patients who underwent perventricular ventricular septal defect device closure, in chronologic order
Patient Age/weight Diagnosis
Preoperative
symptoms Exposure Device size Additional procedures





8 mm Subaortic/VSD patch,
pulmonary valvotomy,
infundibular patch













6 mm Coarctation repair and
arch augmentation
3 4 mo, 4 kg Large anterior muscular
VSD, ASD (multiple
fenestrations) (b)









18 mm Band removal and PA
plasty





6 3 y, 20 kg DORV, TGA, inlet. VSD,
apical muscular VSD,




14 mm VSD enlargement and
LV-aortic baffle, t/d
BDG (e)
ASD, Atrial septal defect; BDG, bidirectional Glenn shunt; CHF, congestive heart failure; CPB, cardiopulmonary bypass; D/C, discharge; LV, left ventricle;
PA, pulmonary artery; PS, pulmonary stenosis; POD, postoperative day; RV, right ventricle; s/p, status post; t/d, take-down; VSD, ventricular septal defect;
Op/Os, left-to-right shunt ratio; DORV, double-outlet right ventricle; TGA, transposition of great arteries; FTT, failure to thrive; ECMO, extracorporeal
membrane oxygenation; TEE, transesophageal echocardiography; URI, upper respiratory tract infection.
(a) Cardiopulmonary bypass was needed only for additional procedures, not for placement of the device, which was performed first in patients 1, 2, 3, and
5 and after PA band removal in patient 4. In patient 6, perventricular closure was accomplished during bypass because the decision to do it was made
during bypass.
(b) TEE showed that the atrial septum had multiple separate openings. By using an aortic punch introduced through a right atrial puncture, a central hole
was created in the floppy septum primum. By use of the technique described, an 11-mm Amplatzer (AGA Medical Corp, Golden Valley, Minn) septal occluder
was positioned and deployed centrally in the ASD.
(c) The LV disk obliterated the entire left apical septum, resulting in no residual shunting. However, the RV disk was difficult to deploy because of the
severely hypertrophied moderator band and apical RV muscle bundles, which essentially filled the entire RV apex (infundibulosinus partition)11 and
prevented the expansion of the RV disk. The RV disk was eventually positioned within the apical muscle bundles with the device microscrew protruding
through the RV free wall puncture site (Figure 4). The screw was secured to the epicardium with a pledget-supported suture. Qp/Qs at the end of the
procedure was 1.5.
(d) This patient was readmitted to his primary hospital 2 weeks postoperatively with nonspecific URI. A catheterization showed the 4-mm residual VSD again
with a Qp/Qs of 1.9. He was discharged after receiving diuretics and afterload-reducing therapy for 24 hours. At 4 months postoperative, he is asymptomatic,
and the residual VSD is down to 2 mm with no ventricular enlargement.
(e) On preoperative studies, the apical muscular VSD had been judged to be insignificant and was left alone initially. Failure to come off of cardiopulmonary
bypass after biventricular repair and evidence of significant left-right shunting across the muscular VSD by TEE led to the decision to close VSD with the
perventricular technique. This was successful in that the muscular VSD was found to be completely occluded by TEE and the patient was weaned off of
CPB. LV hypoplasia prevented successful biventricular repair, and after a 24-hour period of rest on ECMO, the repair was taken-down to an extracardiac
Fontan.
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planes such as DORV or transposition of the great arteries,
the percutaneous retrograde approach to cross MVSDs can
be very challenging. This technique eliminates that issue
because the septum is approached from an anterior and not
a lateral (tricuspid valve) plane. In addition, percutaneous
closure of MVSDs in a child palliated with a pulmonary
artery (PA) band often results in residual shunting after the
PA band is removed.7 As illustrated in patient 4, the present
technique offers the possibility to deband the PA and close
all VSDs using the perventricular approach in 1 setting. As
we also experienced with patient 4, severely hypertrophied
RV muscle bundles make the recognition of the true VSD
margins and correct deployment of the RV disk difficult.
This strengthens our belief that patients with MVSDs
should not be palliated but closed at the time of initial
presentation. Post-infarct VSDs in adults would also be
amenable to this approach whereby one would be able to
avoid prolonged cardioplegic arrest and revascularize the
patient in 1 setting. Furthermore, we have described the first
periatrial device closure of a complex atrial septal defect
(ASD). This approach may be used as an alternative to
traditional ASD closure during CPB in patients with com-
plex ASDs caused by large atrial septal aneurysms or in
large ASDs in which attempts to align the left atrial disk
parallel to the septum may fail because of the angle of
approach.
Conclusion
Despite the limitations of this study (small patient sample, short
follow-up, and lack of randomization), this report demonstrates the
feasibility of off-pump MVSD closure through right perventricular
puncture using the Amplatzer MVSD device. We believe that this
technique may become the initial treatment of choice for any infant
with MVSDs, for older patients with poor vascular access, and for
patients previously palliated with PA bands. As hybrid cardiac
surgery techniques mature, thoracoscopic or robotic puncture of
the RV or the right atrium and device delivery into a VSD or ASD
may be a reality in the near future.
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for reperfusion
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